Clinical pharmacokinetic studies of perphenazine.
نویسندگان
چکیده
منابع مشابه
Clinical Pharmacokinetic Studies of Enzalutamide
BACKGROUND AND OBJECTIVES Oral enzalutamide (160 mg once daily) is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article describes the pharmacokinetics of enzalutamide and its active metabolite N-desmethyl enzalutamide. METHODS Results are reported from five clinical studies. RESULTS In a dose-escalation study (n = 140), enzalutamide half-life w...
متن کاملPharmacokinetic interactions of Hypericum perforatum L. (St John's wort) with conventional drugs: a review of clinical studies
Background and objectives: Hypericum perforatum L., commonly known as St. John’s wort (SJW) from the family Hypericaceae is a famous medicinal plant used to treat mild to moderate depression; so, it might affect the pharmacokinetics of numerous drugs. Due to widespread herb-drug interactions of SJW, this study was designed to review the clinical evidences regarding the...
متن کاملPharmacokinetic Studies of Enrofloxacin in Yak after Intramuscular Administration
The pharmacokinetic studies of enrofloxacin were investigated in yak (Bos grunniens L.) after administration of enrofloxacin by intramuscular route at 5 mgkg-1 body weight. Blood samples were collected from the jugular vein at predetermined time intervals after drug administration. Plasma was separated and analysed for enrofloxacin by reverse-phase high performance liquid chromatography. Variou...
متن کاملPharmacokinetic Studies on Oximes in Organophosphate Poisoning: A Mini Review
Organophosphate (OP) poisoning is one of the most common causes of poisoning in developing countries especially in Southeastern Asia. Poisoning with phosphorus-containing organic chemicals or OP compounds can be managed with antidotes like oximes which are potential reactivators of acetylcholinesterase (AChE). The efficacy of oxime therapy in OP poisoned patients mainly depends upon various fac...
متن کاملPerphenazine 4-aminobutyrate Mesylate
Schizophrenia is a lifelong disorder characterized by bizarre delusions, lack of motivation, reduction in spontaneous speech, social withdrawal and some affective symptoms. Perphenazine 4-aminobutyrate mesylate (CYP-1020) is a novel, mutual prodrug ester of GABA and perphenazine that exhibits potent dopamine D2 receptor antagonist and GABAA receptor agonist activity. In relevant animal models, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 1976
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.1976.tb00647.x